Arrowhead Pharmaceuticalsincis A Biopharmaceutical Company Based In Pasadenacaliforniafounded In 2004The Company Specializes In Developing Gene Silencing Therapeutics Using Rna Interferencernaitechnologyarrowhead Focuses On Treatments For Conditions Such As Hepatitis Bliver Diseases Related To Alpha 1 Antitrypsin Deficiencyand Cardiovascular Diseases The Company Has A Diverse Pipeline Of Productsincluding Aro Apoc3 For Hypertriglyceridemiaaro Ang3 For Dyslipidemiaand Olpasiran For Cardiovascular Diseasearrowhead Has Established Significant Partnerships With Major Pharmaceutical Companiesincluding A Collaboration With Janssen To Develop Aro Hbv For Hepatitis B And Agreements With Amgen For Aro Lpa Targeting Cardiovascular Diseasearrowhead Operates Research Facilities In San Diegocaliforniaand Madisonwisconsinsupporting Its Commitment To Advancing Rnai Technologythe Company Reported A Revenue Of $243 2 Million In 2022 And Employs Around 376 Peoplereflecting Its Growth In The Biopharmaceutical Sector
